Zen Technologies Ltd (ZENTEC) Q1 FY27 Results Analysis: Revenue Slips 10.5%, No New Order Wins
Zen Technologies Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 141.64 Cr (-10.50% YoY) and PAT growth of -27.83% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 25, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 141.64 Cr (-10.50% YoY) |
| PAT (Q1) | Rs. 34.46 Cr (-27.83% YoY) |
| EBITDA margin | 27.34% (-1355 bps YoY) |
| EPS (Q1) | Rs. 3.83 (-27.87% YoY) |
| Market cap | Rs. 15,969.66 Cr |
| CMP | Rs. 1,768.70 |
Quarter Snapshot
ZENTEC's Q1 FY27 results showed a 10.5% YoY revenue decline and significant margin compression, with operational EBITDA margin at 27.34% well below the 35% target. No new order wins were disclosed, and the current run-rate suggests the FY27 revenue target of ~Rs.1,500 Cr is a stretch. Positives include a strong balance sheet, normalized PAT margin achieving the 25% target, and a robust pipeline with DAC approval for large anti-drone systems, but near-term execution remains challenged.
Key Investment Insights
Key Positives
- Normalized PAT margin of 26.43% achieved the long-term target of 25%.
- Standalone revenue grew 43.2% QoQ to Rs.102.96 Cr.
- Finance costs declined 68.5% YoY to Rs.1.09 Cr, reflecting a debt-free balance sheet.
- Seven new products unveiled at North Tech Symposium and ISBS launched.
- DAC approval for Rs.52,000 Cr including AKASH TARANG anti-UAV system enhances order pipeline visibility.
Risk Factors
- Consolidated revenue declined 10.5% YoY to Rs.141.64 Cr, with no new order wins disclosed.
- Operational EBITDA margin contracted to 27.34%, 767 bps below the 35% long-term target.
- Other expenses surged 83.9% YoY to Rs.30.05 Cr, driving margin compression.
- Subsidiary contribution to PAT fell 50.6% YoY to Rs.5.25 Cr.
- Employee costs rose to 24.34% of revenue from 20.08% a year ago.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.